ZHX3

Summary

ZHX3 (zinc fingers and homeoboxes 3, HGNC:15935) is a protein-coding gene on chromosome 20q12, encoding Zinc fingers and homeoboxes protein 3 (Q9H4I2). Acts as a transcriptional repressor.

This gene encodes a member of the zinc fingers and homeoboxes (ZHX) gene family. The encoded protein contains two C2H2-type zinc fingers and five homeodomains and forms a dimer with itself or with zinc fingers and homeoboxes family member 1. In the nucleus, the dimerized protein interacts with the A subunit of the ubiquitous transcription factor nuclear factor-Y and may function as a transcriptional repressor.

Source: NCBI Gene 23051 — RefSeq curated summary.

At a glance

• GWAS associations: 39
• Clinical variants (ClinVar): 251 total
• MANE Select transcript: NM_001384317

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:15935
Approved symbol	ZHX3
Name	zinc fingers and homeoboxes 3
Location	20q12
Locus type	gene with protein product
Status	Approved
Aliases	KIAA0395
Ensembl gene	ENSG00000174306
Ensembl biotype	protein_coding
OMIM	609598
Entrez	23051

Gene structure

Transcript identifiers

Ensembl transcripts: 26 — 19 protein_coding, 7 protein_coding_CDS_not_defined

ENST00000309060, ENST00000373261, ENST00000419740, ENST00000421422, ENST00000432768, ENST00000436099, ENST00000436440, ENST00000485686, ENST00000487057, ENST00000544979, ENST00000558993, ENST00000559028, ENST00000559234, ENST00000559296, ENST00000559436, ENST00000560361, ENST00000560364, ENST00000560456, ENST00000560759, ENST00000561291, ENST00000683867, ENST00000895799, ENST00000895800, ENST00000895801, ENST00000895802, ENST00000912257

RefSeq mRNA: 12 — MANE Select: NM_001384317 NM_001384315, NM_001384316, NM_001384317, NM_001384318, NM_001384319, NM_001384320, NM_001384321, NM_001384322, NM_001384323, NM_001384324, NM_001384325, NM_015035

CCDS: CCDS13315, CCDS93040

Canonical transcript exons

ENST00000683867 — 4 exons

Exon	Start	End
ENSE00001526829	41268990	41269083
ENSE00002546085	41317509	41317731
ENSE00003698803	41202057	41205066
ENSE00003916170	41178455	41185201

Expression profiles

Bgee: expression breadth ubiquitous, 287 present calls, max score 94.91.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 18.0833 / max 160.4231, expressed in 1775 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
187278	14.2950	1763
187279	2.6666	980
187280	1.0539	625
187281	0.0363	15
187276	0.0274	3
187277	0.0042	3

Top tissues by expression

296 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sural nerve	UBERON:0015488	94.91	gold quality
mucosa of stomach	UBERON:0001199	92.56	gold quality
calcaneal tendon	UBERON:0003701	92.24	gold quality
ventricular zone	UBERON:0003053	90.26	gold quality
corpus callosum	UBERON:0002336	90.21	gold quality
stromal cell of endometrium	CL:0002255	90.19	gold quality
lower esophagus muscularis layer	UBERON:0035833	90.02	gold quality
lower esophagus	UBERON:0013473	89.94	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	89.77	gold quality
popliteal artery	UBERON:0002250	89.47	gold quality
tibial artery	UBERON:0007610	89.46	gold quality
tendon	UBERON:0000043	89.09	gold quality
medial globus pallidus	UBERON:0002477	88.86	gold quality
aorta	UBERON:0000947	88.57	gold quality
nucleus accumbens	UBERON:0001882	88.44	gold quality
left testis	UBERON:0004533	88.41	gold quality
caudate nucleus	UBERON:0001873	88.22	gold quality
globus pallidus	UBERON:0001875	88.18	gold quality
descending thoracic aorta	UBERON:0002345	88.08	gold quality
right testis	UBERON:0004534	87.99	gold quality
renal medulla	UBERON:0000362	87.97	gold quality
putamen	UBERON:0001874	87.85	gold quality
hindlimb stylopod muscle	UBERON:0004252	87.84	gold quality
left coronary artery	UBERON:0001626	87.77	gold quality
thoracic aorta	UBERON:0001515	87.50	gold quality
amygdala	UBERON:0001876	87.45	gold quality
right coronary artery	UBERON:0001625	87.39	gold quality
coronary artery	UBERON:0001621	87.38	gold quality
ascending aorta	UBERON:0001496	87.29	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	87.27	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	14.74

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

3 targets.

Target	Regulation
HK2	Repression
ZHX2
ZHX3

Upstream regulators (CollecTRI, top): ZHX2, ZHX3

miRNA regulators (miRDB)

192 targeting ZHX3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-3689D	100.00	66.14	1181
HSA-MIR-6851-5P	100.00	65.63	1294
HSA-MIR-3925-3P	100.00	69.95	1237
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-520G-5P	99.99	66.76	658
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-6845-3P	99.94	66.88	1439
HSA-MIR-1236-3P	99.94	68.04	1695

Literature-anchored findings (GeneRIF, showing 6)

• dimerizes with both ZHX1 and ZHX3, also interacts with the activation domain of the NF-YA (PMID:12659632)
• ZHX proteins 1, 2 and 3 are major transcriptional mediators of podocyte disease (PMID:17056598)
• ZHX3 is involved in the switch from the undifferentiated state of mesenchymal stem cells to an osteogenic program (PMID:21174497)
• ZHX3 expression in renal cell carcinoma (PMID:28152006)
• ZHX3 promotes the progression of urothelial carcinoma of the bladder via repressing of RGS2 and is a novel substrate of TRIM21. (PMID:33440047)
• Loss of the transcription repressor ZHX3 induces senescence-associated gene expression and mitochondrial-nucleolar activation. (PMID:35085309)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	zhx3b	ENSDARG00000019774
danio_rerio	zhx3a	ENSDARG00000087186
mus_musculus	Zhx3	ENSMUSG00000035877
rattus_norvegicus	Zhx3	ENSRNOG00000027988

Paralogs (3): ZHX1 (ENSG00000165156), ZHX2 (ENSG00000178764), HOMEZ (ENSG00000290292)

Protein

Protein identifiers

Zinc fingers and homeoboxes protein 3 — Q9H4I2 (reviewed: Q9H4I2)

Alternative names: Triple homeobox protein 1, Zinc finger and homeodomain protein 3

All UniProt accessions (8): Q9H4I2, A0A0A0MST6, A0A0A0MSU5, F6UBH9, F6UQN6, H0Y6F5, H0YLR4, H0YNY7

UniProt curated annotations — full annotation on UniProt →

Function. Acts as a transcriptional repressor. Involved in the early stages of mesenchymal stem cell (MSC) osteogenic differentiation. Is a regulator of podocyte gene expression during primary glomerula disease. Binds to promoter DNA.

Subunit / interactions. Homodimer (via homeobox domain 1). Heterodimer with ZHX1 (via homeobox domain 1). Heterodimer with ZHX2 (via homeobox domain 1). Heterodimerization with ZHX1 is a prerequisite for repressor activity. Interacts with NFYA.

Subcellular location. Nucleus.

Tissue specificity. Widely expressed. High expression in kidney. Expressed during osteogenic differentiation.

Induction. Up-regulated during osteogenic differentiation of mesenchymal stem cells.

Similarity. Belongs to the ZHX family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9H4I2-1	1	yes
Q9H4I2-2	2

RefSeq proteins (12): NP_001371244, NP_001371245, NP_001371246, NP_001371247, NP_001371248, NP_001371249, NP_001371250, NP_001371251, NP_001371252, NP_001371253, NP_001371254, NP_055850 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001356	HD	Domain
IPR009057	Homeodomain-like_sf	Homologous_superfamily
IPR013087	Znf_C2H2_type	Domain
IPR024578	Homez_homeobox_dom	Domain
IPR036236	Znf_C2H2_sf	Homologous_superfamily
IPR041057	ZHX_Znf_C2H2	Domain

Pfam: PF00046, PF11569, PF18387

UniProt features (40 total): region of interest 8, modified residue 7, helix 7, DNA-binding region 5, compositionally biased region 3, strand 3, zinc finger region 2, sequence conflict 2, chain 1, splice variant 1, sequence variant 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
2DA5	SOLUTION NMR
2DN0	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9H4I2-F1	60.80	0.23

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (7): 599, 604, 680, 708, 723, 927, 946

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 0 (showing top):

GO Biological Process (5): negative regulation of transcription by RNA polymerase II (GO:0000122), regulation of transcription by RNA polymerase II (GO:0006357), cell differentiation (GO:0030154), positive regulation of osteoblast differentiation (GO:0045669), negative regulation of DNA-templated transcription (GO:0045892)

GO Molecular Function (9): RNA polymerase II transcription regulatory region sequence-specific DNA binding (GO:0000977), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription factor activity (GO:0003700), zinc ion binding (GO:0008270), protein homodimerization activity (GO:0042803), protein heterodimerization activity (GO:0046982), DNA binding (GO:0003677), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (3): chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of DNA-templated transcription	3
regulation of transcription by RNA polymerase II	2
transcription by RNA polymerase II	2
transcription cis-regulatory region binding	2
protein dimerization activity	2
cellular anatomical structure	2
negative regulation of DNA-templated transcription	1
cellular developmental process	1
osteoblast differentiation	1
positive regulation of cell differentiation	1
regulation of osteoblast differentiation	1
DNA-templated transcription	1
negative regulation of RNA biosynthetic process	1
chromatin	1
RNA polymerase II transcription regulatory region sequence-specific DNA binding	1
DNA-binding transcription factor activity	1
transcription regulator activity	1
transition metal ion binding	1
identical protein binding	1
nucleic acid binding	1
binding	1
cation binding	1
chromosome	1
intracellular membrane-bounded organelle	1
nuclear lumen	1

Protein interactions and networks

STRING

854 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZHX3	NFYA	P23511	856
ZHX3	ZHX2	Q9Y6X8	485
ZHX3	RPN2	P04844	472
ZHX3	TBC1D31	Q96DN5	456
ZHX3	DHX35	Q9H5Z1	437
ZHX3	SACK1A	Q86UY5	426
ZHX3	LPIN3	Q9BQK8	419
ZHX3	GGT7	Q9UJ14	418
ZHX3	RAB5IF	Q9BUV8	415
ZHX3	BTBD9	Q96Q07	411
ZHX3	TOP1	P11387	407
ZHX3	ZFR	Q96KR1	403
ZHX3	DERL1	Q9BUN8	395
ZHX3	ATAD2	Q6PL18	384
ZHX3	ARHGAP31	Q2M1Z3	376

IntAct

30 interactions, top by confidence:

A	B	Type	Score
ZHX3	NLK	psi-mi:“MI:0915”(physical association)	0.670
ZHX3	RPL7A	psi-mi:“MI:0915”(physical association)	0.400
ZHX3		psi-mi:“MI:0915”(physical association)	0.370
NTAQ1	SBNO1	psi-mi:“MI:0914”(association)	0.350
PDIA6	PLS1	psi-mi:“MI:0914”(association)	0.350
	ARID1A	psi-mi:“MI:0914”(association)	0.350
CSNK2B	OSBPL8	psi-mi:“MI:0914”(association)	0.350
HDAC1		psi-mi:“MI:0914”(association)	0.350
HDAC2		psi-mi:“MI:0914”(association)	0.350
ECHDC2	DBT	psi-mi:“MI:0914”(association)	0.350
AR	MED6	psi-mi:“MI:2364”(proximity)	0.270
RAVER1	KDM6A	psi-mi:“MI:2364”(proximity)	0.270
SRF	ZNF292	psi-mi:“MI:2364”(proximity)	0.270
KLF12		psi-mi:“MI:2364”(proximity)	0.270
KLF3	MCRIP1	psi-mi:“MI:2364”(proximity)	0.270
SOX5	SMCHD1	psi-mi:“MI:2364”(proximity)	0.270
SOX6	SMCHD1	psi-mi:“MI:2364”(proximity)	0.270
YY1	SMCHD1	psi-mi:“MI:2364”(proximity)	0.270
SWSAP1	NACA	psi-mi:“MI:2364”(proximity)	0.270
TLK2	SBNO1	psi-mi:“MI:2364”(proximity)	0.270
SMC5	DKFZp686H10254	psi-mi:“MI:2364”(proximity)	0.270
ZHX3		psi-mi:“MI:0915”(physical association)	0.000
ATXN1	ZHX3	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (62): NLK (Two-hybrid), ZHX3 (Affinity Capture-MS), ZHX3 (Two-hybrid), ZHX3 (Proximity Label-MS), NLK (Two-hybrid), ZHX3 (Affinity Capture-MS), ZHX3 (Affinity Capture-MS), ZHX3 (Affinity Capture-MS), ZHX3 (Reconstituted Complex), ZHX2 (Reconstituted Complex), ZHX2 (Two-hybrid), ZHX3 (Affinity Capture-RNA), ZHX3 (Proximity Label-MS), ZHX1 (Two-hybrid), ZHX3 (Reconstituted Complex)

ESM2 similar proteins: A1YF22, A1YG99, A2T771, A2T7S4, B3DJM5, D3ZKB9, H2L008, O42410, O73590, P34303, P70121, Q03112, Q15652, Q15723, Q19418, Q21502, Q24478, Q2HNT1, Q2HNT2, Q2TB10, Q3UG20, Q58F21, Q5DTH5, Q5R7F2, Q5RCU4, Q61SK8, Q63HK5, Q66J63, Q69ZW3, Q6GN21, Q6P2L6, Q6ZSZ6, Q80VX4, Q86MI0, Q86T24, Q86UP3, Q8BN78, Q8C0C0, Q8CGV9, Q8IZD2

Diamond homologs: A1YF22, A1YG99, A2T771, A2T7S4, P70121, Q5R7F2, Q80VX4, Q80Z36, Q8C0C0, Q8C0Q2, Q8IX15, Q8R515, Q9H4I2, Q9UKY1, Q9Y6X8, Q80W88, Q8K3E9, Q61321, Q9UIU6

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 32 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
chromatin remodeling	5	12.2×	4e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

251 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	166
Likely benign	61
Benign	14

Top pathogenic / likely-pathogenic (0)

SpliceAI

2127 predictions. Top by Δscore:

Variant	Effect	Δscore
20:41268977:A:AC	donor_gain	1.0000
20:41268978:C:CC	donor_gain	1.0000
20:41268988:A:AC	donor_gain	1.0000
20:41268989:C:CC	donor_gain	1.0000
20:41268989:CTT:C	donor_gain	1.0000
20:41268991:T:TA	donor_gain	1.0000
20:41272205:T:TA	donor_gain	1.0000
20:41205063:CAAT:C	acceptor_gain	0.9900
20:41205067:C:CC	acceptor_gain	0.9900
20:41218657:T:TA	donor_gain	0.9900
20:41238686:A:AC	donor_gain	0.9900
20:41238687:C:CC	donor_gain	0.9900
20:41268989:CTTCA:C	donor_gain	0.9900
20:41269079:CAGTC:C	acceptor_gain	0.9900
20:41184989:T:C	donor_gain	0.9800
20:41184993:G:A	donor_gain	0.9800
20:41185004:G:A	donor_gain	0.9800
20:41185978:C:CC	acceptor_gain	0.9800
20:41205062:TCAAT:T	acceptor_gain	0.9800
20:41205063:CAATC:C	acceptor_gain	0.9800
20:41205065:AT:A	acceptor_gain	0.9800
20:41217118:A:T	acceptor_gain	0.9800
20:41268983:T:TA	donor_gain	0.9800
20:41268988:ACTT:A	donor_gain	0.9800
20:41268989:CTTC:C	donor_gain	0.9800
20:41299935:T:A	donor_gain	0.9800
20:41184956:A:AC	donor_gain	0.9700
20:41184957:C:CC	donor_gain	0.9700
20:41200039:AC:A	donor_gain	0.9700
20:41200040:CC:C	donor_gain	0.9700

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000000650 (20:41290704 A>G), RS1000015065 (20:41192844 T>G), RS1000050729 (20:41190505 A>C), RS1000056477 (20:41276774 G>A), RS1000101660 (20:41239854 A>T), RS1000122405 (20:41206296 A>G), RS1000147342 (20:41186499 G>A), RS1000167580 (20:41301842 C>G), RS1000180815 (20:41233242 A>G), RS1000181172 (20:41260839 T>C,G), RS1000197641 (20:41253168 C>T), RS1000199908 (20:41302141 A>G), RS1000217411 (20:41296615 T>C), RS1000228956 (20:41269894 A>C), RS1000252627 (20:41214786 C>A)

Disease associations

OMIM: gene MIM:609598 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

39 associations (top):

Study	Trait	p-value
GCST003804_5	Non-response to bupropion and depression	8.000000e-07
GCST003818_33	Resting heart rate	1.000000e-08
GCST005195_109	Coronary artery disease	1.000000e-08
GCST005196_245	Coronary artery disease	2.000000e-08
GCST005531_98	Multiple sclerosis	7.000000e-08
GCST006004_22	Low density lipoprotein cholesterol levels	7.000000e-09
GCST006034_7	Total cholesterol levels	4.000000e-09
GCST006661_160	Male-pattern baldness	2.000000e-15
GCST006979_542	Heel bone mineral density	7.000000e-45
GCST007515_23	Type 2 diabetes	7.000000e-06
GCST007517_24	Type 2 diabetes	9.000000e-08
GCST007518_32	Type 2 diabetes (adjusted for BMI)	3.000000e-06
GCST007858_9	Fasting blood glucose adjusted for BMI	4.000000e-07
GCST008077_70	LDL cholesterol levels	5.000000e-09
GCST008078_102	LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)	2.000000e-15
GCST008078_32	LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)	1.000000e-09
GCST008079_43	LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)	4.000000e-46
GCST008079_57	LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)	9.000000e-11
GCST008079_84	LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)	4.000000e-46
GCST008086_66	LDL cholesterol levels in current drinkers	1.000000e-09
GCST008839_242	Height	5.000000e-10
GCST009597_310	Multiple sclerosis	5.000000e-06
GCST009597_38	Multiple sclerosis	3.000000e-06
GCST010002_67	Refractive error	7.000000e-10
GCST010703_20	Brain morphology (MOSTest)	1.000000e-09
GCST010866_166	Coronary artery disease	5.000000e-10
GCST011011_40	Youthful appearance (self-reported)	1.000000e-09
GCST011365_7	Myocardial infarction	2.000000e-08
GCST011494_101	Daytime nap	1.000000e-14
GCST90020025_1661	Waist-to-hip ratio adjusted for BMI	7.000000e-10

EFO canonical traits (8, from GWAS)

EFO ID	Trait name
EFO:0004611	low density lipoprotein cholesterol measurement
EFO:0004574	total cholesterol measurement
EFO:0009270	heel bone mineral density
EFO:0004329	alcohol drinking
EFO:0004346	neuroimaging measurement
EFO:0007828	daytime rest measurement
EFO:0007788	BMI-adjusted waist-hip ratio
EFO:0008039	BMI-adjusted hip circumference

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases expression	3
Benzo(a)pyrene	affects methylation, decreases expression	3
Air Pollutants	affects cotreatment, decreases expression, increases abundance	2
Tobacco Smoke Pollution	decreases expression	2
Valproic Acid	affects expression, increases expression	2
Cadmium Chloride	decreases expression, increases expression	2
FR900359	increases phosphorylation	1
dicrotophos	increases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, decreases expression, increases abundance	1
bisphenol A	affects cotreatment, increases expression	1
2-butenal	decreases expression	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
4-aminophenylarsenoxide	affects binding, decreases reaction	1
methacrylaldehyde	affects cotreatment, decreases expression, increases abundance	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
CGP 52608	affects binding, increases reaction	1
ICG 001	increases expression	1
abrine	decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Temozolomide	decreases expression	1
Arsenic Trioxide	affects binding, decreases reaction	1
Acrolein	affects cotreatment, decreases expression, increases abundance	1
Arsenic	affects expression	1
Caffeine	decreases phosphorylation	1
Copper	affects binding, increases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Disulfiram	affects binding, increases expression	1
Doxorubicin	decreases expression	1
Indomethacin	affects cotreatment, increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.